Influence of Gz and Gi2 transducer proteins in the affinity of opioid agonists to mu receptors. 1998

J Garzón, and M Castro, and P Sánchez-Blázquez
Neurofarmacología, Instituto Cajal, Consejo Superior de Investigaciones Científicas, C/Dr Arce 37, 28002 Madrid, Spain. jgarzon@cajal.csic.es

The affinity displayed by different opioids to mu receptors (ORs) was determined in mouse brain membranes incubated with antibodies directed to Galpha subunits of the guanine nucleotide-binding proteins Gi2 and Gz. Assays were conducted with 10 pm 125I-Tyr27-beta-endorphin in the presence of 300 nm N, N-diallyl-Tyr-(alpha-aminoisobutyric acid)2-Phe-Leu-OH (ICI-174 864), which prevented the binding of the iodinated neuropeptide to delta-ORs. Gpp(NH)p or the preincubation of mouse brain membranes with IgGs to Gi2alpha or Gzalpha subunits, promoted reductions in the affinity exhibited by the labelled probe. The potencies of beta-endorphin, [D-Ala2,N-MePhe4,Gly-ol5]-enkephalin (DAMGO) and [D-Pen2,5]enkephalin (DPDPE) were reduced after impairing the coupling of mu-ORs to Gi2 or Gz proteins. Morphine showed a loss of affinity towards the mu-OR after preincubation of membranes with IgGs to Gzalpha subunits. However, it retained its potency after treatment with the anti-Gi2alpha IgGs. Conversely, [D-Ala2, D-Leu5]enkephalin (DADLE) and [D-Ser2, Leu5] enkephalin-Thr6 (DSLET) showed decreased affinity to mu-ORs after treatment with anti-Gi2alpha IgGs, with no noticeable change following the use of IgGs to Gzalpha subunits. The affinity exhibited by the opioid antagonists naloxone, naltrexone, naloxonazine and [Cys2,Tyr3,Orn5, Pen7 amide]somatostatin analogue (CTOP) remained unchanged after either treatment. Therefore, the affinity exhibited by opioid agonists of mu-ORs, but not antagonists, depends on the nature of the G-protein coupled to these receptors.

UI MeSH Term Description Entries
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D007470 Monoiodotyrosine A product from the iodination of tyrosine. In the biosynthesis of thyroid hormones (THYROXINE and TRIIODOTHYRONINE), tyrosine is first iodized to monoiodotyrosine. Iodotyrosine
D008297 Male Males
D009292 Narcotic Antagonists Agents inhibiting the effect of narcotics on the central nervous system. Competitive Opioid Antagonist,Narcotic Antagonist,Opioid Antagonist,Opioid Antagonists,Opioid Receptor Antagonist,Opioid Reversal Agent,Competitive Opioid Antagonists,Opioid Receptor Antagonists,Opioid Reversal Agents,Agent, Opioid Reversal,Agents, Opioid Reversal,Antagonist, Competitive Opioid,Antagonist, Narcotic,Antagonist, Opioid,Antagonist, Opioid Receptor,Antagonists, Competitive Opioid,Antagonists, Narcotic,Antagonists, Opioid,Antagonists, Opioid Receptor,Opioid Antagonist, Competitive,Opioid Antagonists, Competitive,Receptor Antagonist, Opioid,Receptor Antagonists, Opioid,Reversal Agent, Opioid,Reversal Agents, Opioid
D009294 Narcotics Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. Analgesics, Narcotic,Narcotic Analgesics,Narcotic,Narcotic Effect,Narcotic Effects,Effect, Narcotic,Effects, Narcotic
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response

Related Publications

J Garzón, and M Castro, and P Sánchez-Blázquez
December 2002, Molecular pharmacology,
J Garzón, and M Castro, and P Sánchez-Blázquez
June 2002, Journal of neurochemistry,
J Garzón, and M Castro, and P Sánchez-Blázquez
January 1994, Life sciences,
J Garzón, and M Castro, and P Sánchez-Blázquez
September 2005, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
J Garzón, and M Castro, and P Sánchez-Blázquez
January 1989, NIDA research monograph,
J Garzón, and M Castro, and P Sánchez-Blázquez
June 2005, Cellular and molecular neurobiology,
J Garzón, and M Castro, and P Sánchez-Blázquez
April 1997, The Journal of pharmacology and experimental therapeutics,
J Garzón, and M Castro, and P Sánchez-Blázquez
September 2009, The Journal of biological chemistry,
J Garzón, and M Castro, and P Sánchez-Blázquez
January 1990, Progress in clinical and biological research,
Copied contents to your clipboard!